On Oct. 26, 2021, Moderna announced a new Memorandum of Understanding (MoU) to make up to 110 million doses of the Moderna COVID-19 vaccine available to the African Union.

The Company was prepared to deliver the first 15 million doses in the fourth quarter of 2021, 35 million doses in the first quarter of 2022, and up to 60 million doses in second quarter 2022. All doses were offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments.

The Company was also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, in parallel to building an mRNA vaccine manufacturing facility in Africa. This new MoU would be in addition to Moderna’s agreement with COVAX to supply up to 500 million doses of its COVID-19 vaccine from the fourth quarter of 2021 through 2022. Additionally, the Company announced an investment of up to $500 million to plan to build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines at the 50 µg dose level each year.